



15 February 2008  
Australian Securities Exchange

**COMPANY ANNOUNCEMENT (ASX:QRX)**

**RESIGNATION OF COMPANY SECRETARY**

The Company wishes to advise of the resignation of Mr Terrence F Sayer as a Company Secretary to QRxPharma Limited.

The Company notes that Mr Chris J Campbell remains in office as a Company Secretary to QRxPharma Limited and who can be contacted as follows:

Registered office and principal administrative office:

Level 1, 194 Miller Street  
North Sydney NSW 2060  
Australia  
Telephone: +61 2 9492 8021  
Facsimile: +61 2 8920 0314  
Mobile: +61 (0)401 988 444  
Email: [chris.campbell@qrxpharma.com](mailto:chris.campbell@qrxpharma.com)

For more information please contact:  
Chris J Campbell  
Chief Financial Officer and Company Secretary  
Tel: +61 2 9492 8021  
Email: [chris.campbell@qrxpharma.com](mailto:chris.campbell@qrxpharma.com)

**About QRxPharma**

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a focused business strategy to expand the clinical utility and commercial value of marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates, with the focus being on achieving accelerated development paths, reduced development risk and improved patient outcomes. QRxPharma's lead compound, Q8003IR, began Phase 3 clinical trials in November 2007. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: [www.QRxPharma.com](http://www.QRxPharma.com).